Phase 2 FLAVOR clinical trial currently enrolling 150 patients to assess the safety and effectiveness of CYR-064 in treating patients with chronic smell loss following recovery from a viral infection
The global Chronic Smell And Flavour Market is currently valued at US$ 3146 Million in 2023 and is anticipated to expand at a CAGR of 6.4%. Owing to the technological advances in healthcare the market is likely to propel to US$ 5850.2 Million by 2033.Rising cases of flavour loss post covid is expected to drive the c.
/PRNewswire/ Cyrano Therapeutics, a biopharmaceutical company developing medicines for patients with hyposmia (smell loss), announced today that the U.S..
To embed, copy and paste the code into your website or blog:
The firm is pleased to present the latest edition of The Life Sciences Report. This issue features a sampling of recent COVID-19-related client activity in which the firm has been involved, an article on life sciences venture financings in which firm clients participated in the second half of 2019 and the first half of 2020, an interview with Cyrano Therapeutics CEO Rick Geoffrion regarding the Early Feasibility Studies Program for medical device manufacturers, and an article authored by Voler Systems president Walt Maclay on common design mistakes made by medical device start-ups. In addition, the publication includes a recap of the MedTech Emerging Growth Companies 2020 Virtual Roadshow hosted by US-Japan Medtech Frontiers and the Japan Society of Northern California; an interview with Dr. Wasim Malik of Iaso Ventures, the nation s first sector-focused neuroscience and mental health venture capital firm; and a summary of